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Abstract: In men, prostate cancer is one of the most common cancers worldwide and the
second leading cause of death among all cancer types in Europe and North America, with the
numbers of those affected continuing to increase. Recent studies have identified a recurrent
fusion of TMPRSS2 with members of the ETS family of transcription factors in about 80% of
prostate cancer tissues. Among them, the TMPRSS2-ERG fusion accounts for approximately
50% of these cases. TMPRSS2 is highly regulated by androgen receptor and the chromosomal
rearrangement abnormally induces ERG production by androgen. To investigate the effects of
ERG overexpression on its target genes expression and prostate cancer development, plasmids
were first constructed by inserting the truncated ERG into an expression vector in the forward or
reverse directions. A predicted three-dimensional model of the protein structure of the truncated
ERG, along with immunofluorescence assays, suggest that the minor deletion on the N-terminus
does not appear to affect the structure or function of ERG. Results from ERG target gene
expression profile indicate that TMPRSS2-ERG fusion-induced aberrant ERG overexpression
is likely involved in prostate cancer development by enhancing tumor angiogenesis.
Keywords: prostate cancer, androgen receptor, TMPRSS2, ERG, chromosomal translocation

Introduction
Prostate cancer is one of the most prevalent threats to men’s health in the Western
world and it accounts for the second largest number of male cancer deaths in the
United States.1–5 It is understood to be a disease of complex and multifactorial origins.
It appears that race, family history, and age are major factors related to its incidence.
Men who have first-degree relatives with prostate cancer are at increased risk for
the disease, with the risk of developing prostate cancer increasing with the number
of relatives diagnosed.6 Males under the age of 50 have low rates of occurrence.
However, rates increase rapidly after the age of 50 years, with 73 years being the
average age at time of diagnosis.2,7 Because of improvements in the standards of
modern living and advances in medicine, life expectancy has progressively increased
and as a result, prostate cancer incidences are expected to increase proportionally.
Hormone therapy benefits about 80% of prostate cancer patients by retarding the
progression of the disease.8 However, prostate cancer in the majority of the patients
who initially benefited from hormonal therapy will eventually develop into an
aggressive, hormone-independent form, with little hope for further intervention. 9
Despite the high prevalence of prostate cancer, knowledge about the molecular and
cellular mechanisms that underlie the cause of the disease is limited, and no cure yet
exists for late stage prostate cancer.
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The recently identified high incidence recurrent fusion of
TMPRSS2 with members of the E26 transformation-specific
(ETS) family of transcription factors, including ERG, ETV1,
ETV4, and ETV5, in prostate cancer samples has opened a new
field in prostate cancer research.10–12 This is significant not
only for understanding the underlying molecular mechanisms
of prostate cancer development, but also for designing
strategies for diagnosis, prognosis, and the differential
treatment of prostate cancer.10,13,14 About 80% of prostate
tumors contain genomic fusions of TMPRSS2 and members
of the ETS family of transcription factors. Of these, ∼50%
contains TMPRSS2-ERG fusions.15,16 Furthermore, it has been
reported that TMPRSS2-ERG-positive prostate cancers have
more aggressive phenotypes than those of TMPRSS2-ERGnegative cancers.17,18 Consequently, both short-term and
long-term survival rates of patients with such fusions are

A

significantly affected.19 Screening of prostate cancer samples
found that among the 27 ETS factors, ERG is the most
frequently overexpressed.20 The TMPRSS2 gene is located
on chromosome 21 at 21q22.3 (Figure 1A) and encodes for
a type II transmembrane serine protease.21 Normal prostate
cells express little to no detectable TMPRSS2 protein, but
high levels of TMPRSS2 protein have been found in a
large percentage of prostate cancer cells.22 A recent study
has demonstrated that the full-length TMPRSS2 protein
is expressed in LNCaP cells, an androgen-responsive
prostate cancer cell line, but is not detected in the androgenunresponsive prostate cancer cells PC-3 and DU-145.21 The
expression of TMPRSS2 quickly increases in LNCaP cells
after exposure to androgenic hormones indicating that it is
likely a primary androgen receptor (AR) target gene.21 In fact,
the TMPRSS2 promoter region has a 15-bp sequence that
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Figure 1 Chromosomal deletion and TMPRSS2-ERG fusion. A) Ideogram of chromosomal 21. B) Interstitial deletion and formation of the TMPRSS2-ERG fusion. C) Schematic
illustration of the exons and gene sequences in the TMPRSS2-ERG gene fusion. The gray box represents the open reading frame of TMPRSS2 while the striped box represents
the open reading frame of ERG. Each exon is indicated by numbers in the boxes and the numbers above the boxes are the last base of each exon. Sequences at the fusion
junction are indicated and the sequence from TMPRSS2 is underlined.
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contains a consensus AR-responsive element (ARE) which is
likely involved in AR-ARE interaction and in the regulation
of TMPRSS2 expression.23 Previous experiments have also
suggested that the androgen-responsive promoter elements
of TMPRSS2 are implicated in prostate cancer through the
overexpression of members of the E26 transformationspecific (ETS) family.19
One effect of the interstitial 3 Mb deletion from chromosomal region 21q22 is the generation of the TMPRSS2-ERG
fusion gene, which contains the promoter/enhancer region
of the TMPRSS2 gene and a part of the open reading frame
of the ERG gene (Figure 1B). There are at least 17 distinct
TMPRSS2-ERG transcripts generated from fusions between
exons 1, 2, and 3 of TMPRSS2 and exons 2, 3, 4, 5, or 6 of
ERG which have been identified,24 with the most commonly
identified fusion in prostate cancer containing the promoter/
enhancer region and first exon of TMPRSS2 gene and exon 4 of
ERG gene (Figure 1C). ERG is known to be a pivotal transcription factor in cell differentiation and growth control pathways,
and there are lines of evidence to suggest that overexpression
of ERG may be involved in different stage of prostate cancer
development.13,14,16,25 However, the molecular mechanisms
underlying the chromosomal translocation and prostate cancer
development are not known.20 We hypothesize that overexpression of the ETS factors resulting from TMPRSS2-ETS fusion
plays an essential role in prostate cancer development, and
the data from our research suggest that overexpression of the
truncated ERG may affect prostate cancer development, most
likely through enhancing angiogenesis.

Materials and methods
Construction of overexpression
vector, PSG5-ERG
Total RNA was purified from the VCaP prostate cancer
cell line using an RNAqueous-4PCR kit (Ambion, Inc.,
Austin, TX). For cDNA synthesis, 5 µg of total RNA was
reverse transcribed using random primers (Stratagene, La
Jolla, CA) and SuperScript II reverse transcriptase (Invitrogen,
Carlsbad, CA). The truncated open reading frame (ORF) of
ERG was amplified by PCR using the following primers:
Upper primer, 5′-ATGACCGCGTCCTCCTCCAGCGA-3′;
Lower primer, 5′-TTAGTAGTAAGTGCCCAGATGAG-3′.
XhoI and NheI restriction enzyme sites were added to the
upper and lower primer ends, respectively. The full length of
the ORF in the fusion gene was approximately 1.2 kb, and
the amplified PCR product was purified with a Qiagen Gel
Extraction kit (Qiagen, Inc., Valencia, CA). The PCR product
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was cloned into a TOPO-TA vector (Invitrogen). ERG was
then sub-cloned into the PSG5 expression vector (J. Wong lab,
Baylor College of Medicine, Houston, TX) on the XhoI site
using T4 DNA ligase (Promega, Madison, WI). A negative
control was constructed with the insert oriented in the
opposite direction. Orientations were determined by digesting
with NheI (Promega). DNA sequence and cloning junction
were verified by sequencing (University of Pennsylvania
DNA Sequencing Facility, Philadelphia, PA).

Cell culture and transient
transfection
HeLa cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Cellgro, Mediatech, Inc., Herndon, VA)
containing 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA) and 1% antibiotics/antimycotics
(Abx/Amx) (Gibco, Carlsbad, CA). NIH 3T3 cells were
maintained in DMEM (Cellgro, Mediatech, Inc.) containing
10% bovine calf serum (BCS) (Atlanta Biologicals,
Lawrenceville, GA) and 1% Abx/Amx (Gibco). Cells were
incubated at 37 °C and 4.7% CO2. HeLa and NIH 3T3 cells
were transfected with plasmids containing either the forward
insert or the reverse insert, using lipofectamine and PLUS
reagent (Invitrogen). Cells were incubated in reduced serum
opti-modified Eagle’s medium (Opti-MEM) (Gibco) for six
hours. After this six-hour incubation, DMEM containing 1%
Abx/Amx and either 10% FBS or 10% BCS was added to the
HeLa and NIH 3T3 cells, respectively. Cells were incubated
for an additional 36 hours at 37 °C and 4.7% CO2.

Lysis and western blotting
Cells were collected and lysed with EBC buffer containing
20 mM Tris HCl (pH 8.0), 125 mM EDTA, and 0.5% NP-40.
Protein samples were separated by SDS-PAGE electrophoresis
and transferred to a nitrocellulose membrane. All membranes
were stained with Ponceau S Solution to confirm successful
transfer of the proteins (Sigma-Aldrich, St. Louis, MO).
They were then blocked with 5% milk in TBST (Tris-base,
NaCl, and 1% Tween 20, pH 7.6). Proteins were incubated
in 2.5% milk in TBST with ERG-1/2/3 rabbit polyclonal IgG
(0.2 µg/mL) (Santa Cruz Biotechnology, Santa Cruz, CA) as
a primary antibody and donkey-anti-rabbit IgG (0.08 µg/mL)
(Pierce Biotechnology, Rockford, IL) as a secondary antibody.
The blot was stripped and reprobed by anti-actin (1 µg/mL)
(Calbiochem, San Diego, CA) and peroxidase goat antimouse IgM (0.01 µg/mL) (Calbiochem). The blots were
detected using the Super Signal West Pico Chemiluminescent
Substrate detection system (Pierce Biotechnology).
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Immunofluorescence
After transfection and incubation on glass coverslides for
24 hours at 37 °C and 4.7% CO2, HeLa cells were washed
once with 1X phosphate-buffered solution (PBS), fixed with
Cytofix/Cytoperm (BD Biosciences, San Diego, CA), and
blocked for 30 minutes with 1X Perm/Wash (BD Biosciences).
Cells were incubated with primary and secondary antibodies
in 1X Perm/Wash at 37 °C for one hour each. ERG-1/2/3
rabbit polyclonal IgG (Santa Cruz Biotechnology) was
used as a primary antibody (0.2 µg/mL), Alexa Fluor
488 donkey anti-rabbit IgG was used as a secondary
antibody (0.2 µg/mL; Molecular Probes, Eugene, OR), and
bis-benzamide (1 µg/mL, Sigma-Aldrich) was used to stain
the nucleus. Coverslips were mounted on glass slides using
aqueous mounting media containing anti-fading reagent
(Biomeda Corp., Foster City, CA). Slides were examined
with the use of a Nikon Eclipse E800 microscope. Z-stack
images were obtained using an RT Slider Spot camera
(Diagnostic Instruments, Inc., Sterling Heights, MI) and
analyzed with Image-Pro Plus, Version 6.2.0.424 (Media
Cybernetics, Bethesda, MD) and Autoquant X, Version
X2.0.0 (Media Cybernetics) softwares.

Bioinformatic prediction
of three-dimensional structures
Three-dimensional structures corresponding to sequences of
the full-length ERG, the truncated ERG, and the functional
domains were predicted by using bioinformatic softwares.
The MUSTER database was used to generate the threedimensional models of the proteins,26 Jmol was used for
visualization (www.jmol.org), and PFAM was used for the
domain search.27

Analysis of ERG target genes
Total RNA was purified from transiently transfected HeLa
or NIH 3T3 cells using an RNAqueous-4PCR kit (Ambion,
Austin, TX). For cDNA synthesis, 5 µg of total RNA was
reverse transcribed using random primers (Stratagene,
La Jolla, CA) and Superscript II reverse transcriptase
(Invitrogen). ERG target genes were detected by PCR
using the specifically-designed primers (Invitrogen). The
following PCR conditions were used routinely in a Genius
thermal cycler (Techne Inc., Burlington, NJ): one cycle,
95 °C, two minutes; 35 cycles, 95 °C, one minute, 60 °C,
one minute, 72 °C, one minute; one cycle, 72 °C, five
minutes. PCR products were analyzed on a 1% agarose gel
and visualized with ultraviolet light. The amplified bands
were quantified using Image-J software.
16
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Results and discussion
Cloning and overexpression
of the truncated ERG
The TMPRSS2-ERG gene fusion is heterogeneously expressed
due to a variety of interstitial deletions, creating at least
17 distinct transcripts depending on the location of the fusion.
Alternative splicing can cause fusions that occur between
exons 1, 2, or 3 of TMPRSS2 and exons 2, 3, 4, 5, or 6 of
ERG. The most common TMPRSS2-ERG fusion occurs
between exon 1 of TMPRSS2 and exon 4 of ERG (Figure 1C).
In this fusion gene, the native ATG is lost and translation is
assumed to start from the first ATG. The truncated open reading frame (ORF) was amplified from VCaP prostate cancer
cells and was bidirectionally cloned into expression vector
PSG5 as described in Materials and methods (Figure 2A).
As expected, for successful ligations between ERG and
PSG5, XhoI digests of the clones show two distinct bands,
corresponding to the 4.5 kb vector and the 1.5 kb insert
(Figure 2B, lanes 1 and 2). Upon separate digestion with
NheI, plasmids with the insert oriented in the forward direction have one large fragment of approximately 6 kb and a
small undetectable fragment of less than 20 bp, which is not
detectable on the agarose gel (Figure 2B, lane 3). In contrast,
plasmids with the insert cloned in the reverse direction should
contain fragments of 4.5 kb and 1.5 kb, which are of similar
size to digestion with XhoI (Figure 2B, lane 4). These DNA
sequences and orientations were verified by sequencing.
Because of their size, plasmids containing the reverse insert
served as an ideal negative control in future experiments. The
overexpression of the truncated ERG was shown by western
blotting (Figure 2C). The molecular weight of the full-length
ERG has been estimated to be 49 kD. With the deletion of
31 amino acids from the N-terminus, the truncated ERG is
expected to be approximately 45 kD. Figure 2C shows that
after 36 hours of transient transfection with PSG5-ERG, both
NIH3T3 and HeLa cell lines overexpress a protein of approximately 45 kD. In contrast, cells transfected with no DNA or
with the vector containing a reverse ERG insert exhibit no
bands. This indicates that the truncated ERG was successfully
cloned and overexpressed in both cells. During the preparation
of this manuscript, a published paper verified that the truncated
ERG from the TMPRSS2-ERG fusion is indeed translated with
the first ATG as an alternative translation initiation site.15

Predicted three-dimensional
structure of the truncated ERG
The ERG used in these experiments is modeled after the
most common TMPRSS2-ERG fusion which occurs between
Pathology and Laboratory Medicine International 2009:1

Dovepress
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Figure 2 Cloning and overexpression of truncated ERG. A) Schematic strategy in cloning of the truncated ERG into the expression vector PSG5. B) Verification of the
insertion by enzyme digestion restriction. Lanes 1 and 3: Forward clone; and lanes 2 and 4: Reverse clone. C) Overexpression of truncated ERG. C: transfection with no DNA;
F: transfected with Forward clone; and R: transfected with Reverse clone. tERG: truncated ERG. The actin serves as internal control.

exon 1 of TMPRSS2 and exon 4 of ERG. The use of an
alternate ATG start codon generates a truncated ERG, which
deletes 31 amino acids from the N-terminus of the protein.
However, this truncation does not affect the DNA binding
domain (ETS) or the integrity of the pointed domain (PTN,
Figure 3A), which is particularly important for both dimerization and recruitment of other transcriptional factors.28

A

ADT1

To determine if the truncation of ERG affects the structure of
the protein, we analyzed sequences of both the full-length and
truncated ERG with bioinformatic softwares. The predicted
three-dimensional structure of the truncated ERG appears to
be very similar to that of the full-length protein. Both visibly
contain five alpha helices (colored in pink) and multiple beta
sheets (shown in yellow, Figure 3B). Although the software

PNT

ETS

ADT2

B

ERG

tERG
Jmol

Jmol

Figure 3 Schematic drawing of the truncated ERG protein A) and modeled three-dimensional protein structure B) of the truncated ERG.The activation domains, ADT1 and
ADT2, are located in the N- and C-termini, respectively. PNT represents the pointed domain and ETS represents the ETS-binding site. The gray box depicts the 31 amino
acid deletion from the N-terminus. Predicted three-dimensional models of the protein structures of the full-length ERG and truncated ERG show that the overall structure
of the truncated ERG appears to be similar to that of the full length. The alpha helices are shown in pink and the beta sheets were in yellow.
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has limited capabilities and could not specifically identify the
location of the deletion, the overall structures of the native
ERG and the truncated ERG are similar. This suggests that
the small truncation in the ORF of ERG does not affect the
overall protein structure significantly.

Overexpressed truncated ERG
protein localizes to the nucleus
Since ERG is a transcription factor that binds to the promoter
regions of target genes, its function depends on its ability
to locate to the nucleus. The nuclear translocation signal
sequence has not been identified for ERG. We cannot
completely exclude the possibility that it is located in the
deleted N-terminus. Therefore, it is important to verify that
the nucleus translocation is not affected by the deletion.
Immunofluorescent microscopy was performed on HeLa
cells transiently transfected with no ERG or with plasmids
containing either the forward or reverse ERG insert. Threedimensional images show that cells transfected with the
forward insert exhibit intense green staining intermingled
with blue nuclear staining, signifying that the protein is

No DNA

not simply residing in cytosolic areas around the nucleus
(Figure 4, middle panel). This indicates that the truncated
ERG is located in the nucleus. Control cells transfected
with no ERG (Figure 4, left panel) or with the reverse
insert (Figure 4, right panel) do not express ERG in their
nuclei, as evidenced by the lack of green staining. Since
cells transfected with PSG5-ERG demonstrate no signs of
impaired ERG nuclear localization, this suggests that the
small truncation in the ERG does not have a significant effect
on subcellular location.

Overexpression of truncated ERG
and regulation of target gene expression
Although the cellular functions of ERG have been
established, the genes as well as the genetic pathways
regulated by the TMPRSS2-ERG gene fusion product have
not been characterized. However, because ERG is a pivotal
transcription factor, it is reasonable to speculate that its
actions are mediated through the regulation of its target genes.
It is expected that the TMPRSS2-ERG gene fusion will first
induce ERG overexpression and the overexpressed ERG will

Forward

Reverse

Figure 4 ERG is expressed in nuclei of cells transfected with PSG5-ERG. HeLa cells transfected with plasmids containing the forward insert, the reverse insert, or no DNA were
fixed, permeabilized, and stained for ERG (Green) using ERG-1/2/3 rabbit polyclonal IgG as the primary antibody and Alexa Fluor 488 donkey anti-rabbit IgG as the secondary
antibody. Bis-benzamide (Blue) was used for nuclear staining. Images are taken with a 60X objective. The top and bottom panels are top- and side-views, respectively.
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then affect the expression of its target genes either through
activation or repression. Ultimately, it is the combinations
of the target gene products that will lead to prostate cancer
development. Previous literature has found that there is a
wide variety of target genes that are up- or downregulated
by ERG. Through comparison of the ERG-positive and
ERG-negative prostate cancers, Iljin and colleagues identified a wide array of genes up- or downregulated by ERG.20
Based on the microarray data, a broad screening of seven
ERG target genes was first conducted by reverse transcriptase-polymerase chain reaction (RT-PCR) using specifically
designed primers (Table 1). It was initially determined that
three genes, AGT, GPR116, KHDRBS3, appear to be upregulated, whilst the RAMP1 is downregulated in certain degrees
by ERG overexpression in both HeLa and NIH3T3 cells. Our
results are consistent with the previous findings.20 However,
the AGT appears to be affected the most. Figure 5 showed
that the mRNA level of AGT is significantly upregulated in
cells transfected with the forward insert. In contrast, cells
transfected with the reverse insert do not exhibit this effect
and express levels comparable to those of control cells
transfected with no DNA. GAPDH, a housekeeping protein,
was used as a loading control.
We speculate that aberrant expression of the truncated
ERG could enhance prostate cancer angiogenesis through
upregulating AGT expression. The human AGT gene, located
on chromosome 1, consists of 5 exons and 4 introns and
encodes for angiotensinogen. Angiotensinogen (AGT) is a
452-amino acid glycoprotein that is synthesized and secreted

mainly by the liver, but also by the brain.29,30 So far, it is
the only known precursor of angiotensin I (Agt I), which
is produced when AGT is cleaved by renin, an enzyme
secreted by the kidneys. Agt I is a decapeptide which remains
inactive, with no known function except to be converted
by angiotensin-converting enzyme (ACE) into its active
form, angiotensin II (Agt II). Agt II plays a major role in
the renin-angiotensin system (RAS) and acts as a hormone
through its interactions with its specific angiotensin receptors,
AT1 and AT2.31 Renin, AGT, ACE, Agt II, and the angiotensin
receptors have been found in the human prostate, prostate
cancer cell lines, and rat prostatic cells.32,33 The presence of
Agt II has been observed in basal cells of the normal prostate,
as well as in proliferating neoplastic cells in high grade
prostatic intraepithelial neoplasia and malignant prostate
cancer cells.34,35 Agt II has been shown to increase the rate of
proliferation of prostate cancer cells and it may act as an early
marker of malignancy.32,33,35 It has been suggested that Agt II
is a cell proliferative factor due to the fact that blocking its
receptors has been shown to have anti-proliferative activity,
as well as roles in decreasing prostate-specific antigen and
improving the statuses of patients with hormone-refractory
prostate cancer.34,35 Other research has provided evidence that
Agt II induces oxidative stress, which may lead to prostate
cancer.36 Chronic inflammation has long been associated
with the development of cancer, by releasing reactive oxygen
species that cause permanent DNA damage and genomic
alterations, particularly in proliferating epithelium. 37–39
Agt II is involved in a variety of signaling pathways and

Table 1 Primers used in reverse transcriptase-polymerase chain reaction
Name of the genes

Abbreviations

Primer sequences

Angiotensinogen

AGT

Upper: 5′-CTCTCTGGACTTCACAGAACTGGA-3′
Lower: 5′-GGGAGTTTTGCTGGAAAGTGAGAC-3′

Ca2+-dependent secretion activator

CADPS

Upper: 5′-TACTATCTTGGAAGGAGTGCTGGC-3′
Lower: 5′-TTCACTCACTGATGCTGTGGCTTC-3′

Ca2+-dependent activator protein
for secretion 2

CADPS2

Upper: 5′-CAGTGACGATGAACAAGACCGCAT-3′
Lower: 5′-ACTCCATTTCGGGCGCAATACTC-3′

G protein-coupled receptor 116

GPR116

Upper: 5′-GGGAGTGGAATGGAACCTATCACT-3′
Lower: 5′-GGCATGTGATGTTTTCCCCAGGAA-3′

KH domain containing, binding,
signal transduction associated 3

KHDRBS3

Upper: 5′-CTGCGCCTGGTGAACCAAGAAATA-3′
Lower: 5′- ATAAGCTTCTGCAGGTGGGGCAAA-3′

Phospholipase A2, group VII
(platelet-activating factor
acetylhydrolase, plasma)

2G7

Upper: 5′-AAGTACTGATGGCTGCTGCAAGCT-3′
Lower: 5′-CATGAGATGCCAGGTCAATGCCAA-3′

Receptor activity modifying
protein 1

RAMP1

Upper: 5′-ATCACCTCTTCATGACCACTGCC-3′
Lower: 5′-TACACAATGCCCTCAGTGCGCTT-3′

Glyceraldehyde-3-phosphate
dehydrogenase (control)

GAPDH

Upper: 5′-ACAGCCTCAAGATCATCAGCAA-3′
Lower: 5′-ACCACTGACACGTTGGCAGT-3′
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Figure 5 ERG overexpression and regulation target gene expression. A) Total RNA
was purified from transfected HeLa cells and cDNA was created. ERG target gene
AGT was detected by RT-PCR. GAPDH was used as a loading control. B) Western
blot to show the levels of the overexpressed truncated ERG. Actin serves an internal
control. C) Histogram of the AGT expression regulated by ERG overexpression. The
intensities of the amplified band were quantified using Image-J software. The mRNA
levels were normalized with the internal control GAPDH. C: transfection without
DNA; F: transfected with Forward clone; and R: transfected with reverse clone.

it has been shown to stimulate the production of reactive
oxygen species by upregulating NAD+/NADP+ (NADPH)
oxidases.34,35 Additional studies have demonstrated that
there are increased levels of reactive oxygen species-related
enzymes and hydrogen peroxide in prostatic epithelial
neoplasia and cancer.40
In summary, we have successfully cloned and overexpressed the truncated ERG corresponding to the product
of TMPRSS2-ERG fusion in both NIH3T3 and HeLa
cells. Three dimensional modeling shows that the small
N-terminus deletion has little effect in the overall structure.
Immunostaining demonstrated that the overexpressed
truncated ERG takes a nuclear location. More importantly,
overexpression of truncated ERG leads to the upregulation
of its target gene AGT. Lines of evidence from previous
research suggest that AGT plays some roles in prostate cancer
development. We speculate that one of the mechanisms for
the overexpression of the truncated ERG from TMPRSS2ERG fusion is enhancing angiogenesis through upregulation
of angiotensinogen.
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